The biopharma industry is rapidly advancing, with the cell and gene therapy (CGT) market valued at $18 billion, including 27 approved gene therapies, 65 approved cell therapies, and 26 RNA therapies as of 2023. Vaccine and antibody development, driven by innovations in mRNA and SiRNA strategies, represents a $100 billion market.

In this space, qPCR (quantitative Polymerase Chain Reaction) plays a crucial role in drug development, aiding in lead identification, biomarker discovery, biodistribution analysis, and quality control, ensuring faster drug trials while adhering to regulatory standards. Thermo Fisher Scientific offers a robust qPCR portfolio designed to support drug development from research to commercial-scale production, with solutions like the QualTrak™ Portal that streamline purchasing decisions and ensure regulatory compliance.

Their innovative products, such as the TaqMan™ Cells-to-CT™ Express Kit, eliminate RNA isolation steps, enhancing workflow efficiency and saving up to 90% plastic usage. Automation tools like the Orbitor™ RS2 Microplate Mover and QuantStudio™ instruments enable high-throughput screening, processing up to 10,000 samples in 24 hours. To further streamline data analysis, Diomni™ Enterprise Software reduces analysis time by up to three hours per plate. All TaqPath™ products are manufactured in ISO-certified, FDA-registered facilities, following cGMP standards, ensuring quality and consistency. Thermo Fisher also offers comprehensive service plans, such as the AB Ascend Plan, which provides rapid on-site issue resolution and routine maintenance to minimize downtime, making it easier for biopharma companies to maintain speed, efficiency, and regulatory compliance throughout the drug development process.